Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 23;10(30):2855–2868. doi: 10.18632/oncotarget.26869

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2019 Lampert et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Waterfall plot (A) and duration on the study (B). (A) Twenty-five patients with baseline and subsequent imaging reassessment are shown. Best RECIST response is graphed for each patient. Five patients did not have reassessment scans for comparison (withdrew consent [n = 2], and off-treatment due to intercurrent illness [n = 3]). (B) All 30 patients are shown in a swimmer plot. Color code defines dose level of treatment. Dose level 1: olaparib 400 mg bid days 1–7 with carboplatin AUC3; dose level 2 and expansion cohort: olaparib 400 mg bid days 1–7 with carboplatin AUC4; dose level 3: olaparib 400 mg bid days 1–7 with carboplatin AUC5.